Ischemic and Bleeding Events of Ticagrelor Monotherapy in Korean Patients With and Without Diabetes Mellitus: Insights From the TICO Trial

Medicine and Dentistry

• Ticagrelor 100%
• Combination Therapy 63%
• Monotherapy 63%
• Antiplatelet 63%
• Patient 54%
• Diabetes Mellitus 36%
• Bleeding 36%
• Patient with Diabetes 36%
• Myocardial Infarction 27%
• Hazard Ratio 27%
• Diabetes 18%
• Percutaneous Coronary Intervention 18%
• Blood Clot Lysis 18%
• Analysis 18%
• Inpatient 18%
• Incidence 18%
• Transient Ischemic Attack 9%
• Follow up 9%
• Complication 9%
• Rapamycin 9%
• Group Therapy 9%
• Brain Ischemia 9%
• Acetylsalicylic Acid 9%
• Revascularization 9%
• Stent Thrombosis 9%
• Death 9%
• Introspection 9%
• Stent 9%

Neuroscience

• Ticagrelor 100%
• Diabetes 54%
• Diabetes Mellitus 27%
• Myocardial Infarction 27%
• Ischemic Stroke 9%
• Sirolimus 9%
• Transient Ischemic Attack 9%
• Acute Coronary Syndrome 9%
• Aspirin 9%